Journal
JOURNAL OF DERMATOLOGICAL TREATMENT
Volume 26, Issue 4, Pages 329-334Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/09546634.2014.991673
Keywords
Acitretin; ciclosporin; fumaric acid esters; methotrexate; pregnancy
Categories
Funding
- Abbott/AbbVie
- Almirall-Hermal
- Amgen
- BASF
- Biogen Idec
- Celgene
- Centocor
- Eli Lilly
- Forward Pharma
- Galderma
- Janssen
- Leo Pharma
- Medac
- MSD
- Miltenyi Biotech
- Novartis
- Pfizer
- Teva
- VBL
- Xenoport
- Abbvie
- Actelion
- GSK-Stiefel
- Sandoz
- Trident
- UCB
Ask authors/readers for more resources
The effects of conventional systemic therapies for psoriasis on pregnancy outcomes, lactation, male fertility and mutagenicity are common concerns in the clinical setting. There is relatively little evidence to guide clinician and patient. In this study, we review the safety profile of the commonly used conventional systemic therapies used for psoriasis in individuals of reproductive potential. Safety data are derived from large-scale registries, adverse-event reporting databases, clinical trials and case reports. We assess the effect of each therapy on adverse pregnancy outcomes, including congenital malformations, and lactation with maternal administration. We also assess the effect of the therapies on male fertility and potential mutagenicity with paternal administration. We provide applicable guidance to inform clinician and patient before and after conception.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available